期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

第46届欧洲肝病年会丙型肝炎病毒感染临床研究要点概述 被引量：6

An introduction of the researches on hepatitis C virus infec- tion from the 46th EASL annual conference
原文传递
导出
摘要 第46届欧洲肝病年会于2011年3月在柏林召开，会议期间正式发布了《欧洲肝病学会（EASL）临床实践指南：丙型肝炎病毒感染的处理》。此次会议中，抗病毒治疗是慢性丙型肝炎病毒感染相关研究的重点，主要突出5个方面：（1）标准治疗【聚乙二醇干扰素（Peg－IFN）α或α一2a联合利巴韦林】加用Telaprevir或Boceprevir形成三联治疗；
作者 魏来
机构地区 北京大学人民医院北京大学肝病研究所
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2011年第6期412-414,共3页 Chinese Journal of Hepatology
关键词 肝炎病毒 丙型 干扰素G 利巴韦林 抗病 毒药 会议[文献类型] Hepatitis C virus Interferon-alpha Ribavirin Antiviral agents Congresses[publication]
分类号 R51 [医药卫生—内科学]
  • 相关文献

参考文献17

  • 1Crax i A. EASL clinical practice guidelines: management of hepa- tiffs C virus infection. J Hepatol, 2011 Feb 28. [Epub ahead of print].
  • 2Sulkowski MS, Ceasu E, Asselah T, et al. SILEN-CI: sustained vi- rologic response (SVR) and safety of BI1201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV infection. J Hepatol, 2011, 54: S27.
  • 3Zeuzem S, Andreone P, Pol S, et al. REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. J Hepatol, 2011, 54: S3.
  • 4Jacobson LM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol, 2011, 54: S542.
  • 5Flamm S, Lawit E, Jacobson J, et al. High sustained virologic re- sponse (SVR) among genotyping 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2a/ribavirin. J Hepatol, 2011, 54: S541.
  • 6Zeuzem S, Foster GR, Fried MW, et al. The ASPIRE trial: TMC435 in treatment- experienced patients with genotyping-1 HCV infec- tion who have failed previous PEGIFN/RBV treatment. J Hepatol, 2011, 54: S546.
  • 7Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS- 790052, BMS-650032 and peg-IFNRBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol, 2011, 54: S536.
  • 8McPhee F, Hernandez D, Yu F, et al. Charactarizaion of virologic escape in HCV gentotype 1 null responders receiving a combina- tion of the NS3 protease inhibitor BMS-650032 and NS5A inhibi- tor BMS-790052. J Hepatol, 2011, 54: S28.
  • 9Chevaliez S, Rodriguez C, Soulier A, et al. Molecular characteriza- tion of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: pre-existing resistant variants and dynamics of re- sistant populations. J Hepatol, 2011, 54: S30.
  • 10Hebner C, Harris J, Oldach D, et al. Emergence and persistence of NS5b mutations following combination treatment with tegobuvir (GS-9190) plus standard of care--long-term follow-up from the phase II b study GS-US-196-0103. J Hepatol, 2011, 54: S478.

同被引文献33

引证文献6

二级引证文献7

中华肝脏病杂志
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部